La chaîne d'options affiche les données clés des options sur actions de X4 Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour X4 Pharmaceuticals..

X4 Pharmaceuticals (NASDAQ:XFOR) Stock, Chaîne d'Options

X4 PHARMACEUTICALS INC

X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc Warrants (12/04/2024)

Earnings

Press Releases

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

News

Health Care

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

General

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Financing

Management

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Mag 7 Stocks Under $5 Stocks: ATNF RMBL LOOP XFOR – Breakout Setups – More Stocks Inside

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Markets

ATNF

GEVO

LOOP

PRSO

RMBL

SNYR

XFOR

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Boundless Bio

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

FibroBiologics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Kezar Life Sciences

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma Co

LAVA Therapeutics

Medicus Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Pluri

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Plus Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Comments

X4 Pharmaceuticals

X4 Pharmaceuticals (XFOR) Options

X4 Pharmaceuticals (NASDAQ:XFOR) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL